Skip to content

Evaluating of REVOLA PURESENCE mesotherapy solution for skin rejuvenation

Evaluating of safety and efficacy of REVOLA PURESENCE mesotherapy solution for skin rejuvenation and hydration

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190210042676N41
Enrollment
20
Registered
2025-02-06
Start date
2025-02-18
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

skin hydration. Changes in skin texture

Interventions

Intervention group: 3 sessions with 2-3 cc of REVOLA PURESENCE injectable solution made by Novajen Daru CO, with an 3 weeks interval. Ingredients: Sodium hyaluronate, dexpanthenol, pyridoxine, cyanoco

Sponsors

Novajen Daru Co.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 35 and 60 years old Present visible signs of skin ageing symptoms mainly skin dryness skin roughness, loss of elasticity and appearance of fine lines Possibility to accompany the visit plans and study process Signing an informed consent form and agreed to follow up.

Exclusion criteria

Exclusion criteria: Previous treatment with hyaluronic acid fillers in the facial area within the past year Systemic diseases affecting skin health such as collagen vascular diseases, diabetes, hypothyroidism, as well as liver and renal failure Experience with RF, rejuvenation lasers or intense pulsed light in the past 6 months History of systemic use of skin-related medicine such as glucocorticoids, isotretinoin, immunomodulators and hormonal medicine in the past 3 months Smoking in the past two years

Design outcomes

Primary

MeasureTime frame
Skin elasticity. Timepoint: Before intervention, 4 and 8 weeks after the last injection. Method of measurement: Cutometery.

Secondary

MeasureTime frame
Trans Epidermal Water Loss. Timepoint: Before intervention, 4 and 8 weeks after the last injection. Method of measurement: Tewameter.;Thickness and density of dermis. Timepoint: Before intervention, 4 and 8 weeks after the last injection. Method of measurement: Skin ultrasound.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026